Mandate

Vinge advises Lantmännen in connection with its acquisition of the Vaasan Group

January 15, 2015

Vinge advises Lantmännen Ek För (”Lantmännen”) in connection with its acquisition of the Vaasan Group (”Vaasan”) from Lion Capital. In 2013, Vaasan had net sales of approx. MEUR 415 and in total approx. 2,745 employees. Vaasan is engaged in the baking industry in the Nordic and Baltic regions and is a worldwide supplier of thin crisp and crisp bread. The purchase price is confidential. The transaction is conditional upon approval by the relevant competition authorities.

Vinge’s team consists of responsible partner Christina Kokko, partner Jonas Johansson and associates Sofie Bjärtun and Alex Miler. Associate Malin Malm has advised on IP matters, Matilda Gustafsson and Johan Cederblad have advised on environmental and real property matters, Anders Morén has advised on financing matters and Sara Strandberg has advised on employment law. Partner Marcus Glader and associates Grant McKelvey, Emil Fahlén Godö, Johan Wahlbom and Victoria Grossmann are advising on the competition law aspects of the transaction.

Vinge has also coordinated the work performed by Castrén & Snellman (Finland), Lawin (Estonia, Latvia and Lithuania), Haavind (Norway), Bech-Bruun (Denmark) and Heuking Kühn Lüer Wojtek (Germany).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026